Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nonalcoholic fatty liver disease burden: Australia, 2019–2030
Leon A. Adams, Stuart K. Roberts, Simone I. Strasser, et al.
Journal of Gastroenterology and Hepatology (2020) Vol. 35, Iss. 9, pp. 1628-1635
Open Access | Times Cited: 93

Showing 1-25 of 93 citing articles:

Global incidence and prevalence of nonalcoholic fatty liver disease
Margaret LP Teng, Cheng Han Ng, Daniel Q. Huang, et al.
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S32-S42
Open Access | Times Cited: 316
Changing epidemiology, global trends and implications for outcomes of NAFLD
Vincent Wai‐Sun Wong, Mattias Ekstedt, Grace Lai‐Hung Wong, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 3, pp. 842-852
Open Access | Times Cited: 280
Population screening for liver fibrosis: Toward early diagnosis and intervention for chronic liver diseases
Pere Ginés, Laurent Castéra, Frank Lammert, et al.
Hepatology (2021) Vol. 75, Iss. 1, pp. 219-228
Open Access | Times Cited: 187
Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Michael H. Le, Yee Hui Yeo, Biyao Zou, et al.
Clinical and Molecular Hepatology (2022) Vol. 28, Iss. 4, pp. 841-850
Open Access | Times Cited: 163
Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1,201,807 persons
Michael H. Le, David M. Le, Thomas C. Baez, et al.
Journal of Hepatology (2023) Vol. 79, Iss. 2, pp. 287-295
Closed Access | Times Cited: 155
Review article: the epidemiologic burden of non‐alcoholic fatty liver disease across the world
Linda Henry, James M. Paik, Zobair M. Younossi
Alimentary Pharmacology & Therapeutics (2022) Vol. 56, Iss. 6, pp. 942-956
Closed Access | Times Cited: 139
Healthcare and socioeconomic costs of NAFLD: A global framework to navigate the uncertainties
Alina M. Allen, Jeffrey V. Lazarus, Zobair M. Younossi
Journal of Hepatology (2023) Vol. 79, Iss. 1, pp. 209-217
Open Access | Times Cited: 81
Global burden of primary liver cancer by five etiologies and global prediction by 2035 based on global burden of disease study 2019
Yuan Liu, Jinxin Zheng, Jialing Hao, et al.
Cancer Medicine (2022) Vol. 11, Iss. 5, pp. 1310-1323
Open Access | Times Cited: 80
Geographical similarity and differences in the burden and genetic predisposition of NAFLD
Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gómez, Salvatore Petta, et al.
Hepatology (2022) Vol. 77, Iss. 4, pp. 1404-1427
Closed Access | Times Cited: 76
Lipid accumulation product (LAP) index for the diagnosis of nonalcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis
Menooa Ebrahimi, Seyed Arsalan Seyedi, Seyed Ali Nabipoorashrafi, et al.
Lipids in Health and Disease (2023) Vol. 22, Iss. 1
Open Access | Times Cited: 54
MAFLD enhances clinical practice for liver disease in the Asia-Pacific region
Takumi Kawaguchi, Tsubasa Tsutsumi, Dan Nakano, et al.
Clinical and Molecular Hepatology (2021) Vol. 28, Iss. 2, pp. 150-163
Open Access | Times Cited: 76
Hepatocellular and extrahepatic cancers in non-alcoholic fatty liver disease: A systematic review and meta-analysis
James A. Thomas, Bradley J. Kendall, Christine Dalais, et al.
European Journal of Cancer (2022) Vol. 173, pp. 250-262
Closed Access | Times Cited: 59
From MAFLD to hepatocellular carcinoma and everything in between
Sarah Da Won Bae, Jacob George, Liang Qiao
Chinese Medical Journal (2022) Vol. 135, Iss. 5, pp. 547-556
Open Access | Times Cited: 45
Exercise in the Management of Metabolic-Associated Fatty Liver Disease (MAFLD) in Adults: A Position Statement from Exercise and Sport Science Australia
Shelley E. Keating, Angelo Sabag, Kate Hallsworth, et al.
Sports Medicine (2023) Vol. 53, Iss. 12, pp. 2347-2371
Open Access | Times Cited: 38
Sarcopenia as a Risk Factor for Mortality in NAFLD: How Should We Diagnose It?
Catherine Stankevicius, R H Davis, Dep Huynh, et al.
Journal of Digestive Diseases (2025)
Closed Access | Times Cited: 1
Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
Zobair M. Younossi, Homie Razavi, Michael S. Sherman, et al.
Alimentary Pharmacology & Therapeutics (2025)
Closed Access | Times Cited: 1
Is there an association between non-alcoholic fatty liver disease and cognitive function? A systematic review
Elena S. George, Surbhi Sood, Robin M. Daly, et al.
BMC Geriatrics (2022) Vol. 22, Iss. 1
Open Access | Times Cited: 35
Metabolic dysfunction‐associated steatotic liver disease in older adults is associated with frailty and social disadvantage
Daniel Clayton‐Chubb, William Kemp, Ammar Majeed, et al.
Liver International (2023) Vol. 44, Iss. 1, pp. 39-51
Open Access | Times Cited: 18
Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)—A Condition Associated with Heightened Sympathetic Activation
Revathy Carnagarin, Kearney Tan, Leon A. Adams, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4241-4241
Open Access | Times Cited: 39
Detecting non-alcoholic fatty liver disease and risk factors in health databases: accuracy and limitations of the ICD-10-AM
Kelly L. Hayward, Amy Johnson, Leigh U. Horsfall, et al.
BMJ Open Gastroenterology (2021) Vol. 8, Iss. 1, pp. e000572-e000572
Open Access | Times Cited: 36
Screening for NAFLD—Current Knowledge and Challenges
Roberta Forlano, Giordano Sigon, Benjamin H. Mullish, et al.
Metabolites (2023) Vol. 13, Iss. 4, pp. 536-536
Open Access | Times Cited: 15
Therapeutic siRNA targeting PLIN2 ameliorates steatosis, inflammation, and fibrosis in steatotic liver disease models
Yao Wang, Jiaxin Zhou, Qi Yang, et al.
Journal of Lipid Research (2024) Vol. 65, Iss. 10, pp. 100635-100635
Open Access | Times Cited: 5
Metabolic associated fatty liver disease: Addressing a new era in liver transplantation
Madeleine Gill, Avik Majumdar
World Journal of Hepatology (2020) Vol. 12, Iss. 12, pp. 1168-1181
Open Access | Times Cited: 38
Changing clinical management of NAFLD in Asia
T. Nakatsuka, Ryosuke Tateishi, Kazuhiko Koike
Liver International (2021) Vol. 42, Iss. 9, pp. 1955-1968
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top